Abstract

BACKGROUND: Among many protocols for treatment of exudative AMD, combined therapy of anti-VEGF agents and non-steroidal anti-inflammatory drugs (NSAIDs) seems to be an ideal alternative to monotherapy based on ranibizumab or bevacizumab. The aim of this study was to evaluate the effectiveness of aflibercept and bromfenac in the treatment of exudative AMD.

MATERIAL AND METHODS: The study was conducted on a group of 27 patients with exudative AMD who were administered intravitreal aflibercept and topical bromfenac (study group) once a month. Additional injections were administered up to 3 months after the third administration, depending on response to treatment. The control group consisted of subjects treated with aflibercept only. Visual acuity and anatomical outcomes in optical coherence tomography (OCT) were assessed at baseline visit, 4 months after the first dose, and 6 months after the start of the treatment.

RESULTS: Visual acuity improved over time in the study group and the differences between the groups were statistically significant. No statistically significant differences were found in OCT parameters.

CONCLUSIONS: Combined therapy of aflibercept and bromfenac in the treatment of wet AMD is more effective than single aflibercept therapy.

Keywords: Benzophenones - administration & dosage, Bromobenzenes - administration & dosage, Drug Therapy, Combination, Macular Degeneration - physiopathology, Pilot Projects, Receptors, Vascular Endothelial Growth Factor - administration & dosage, Recombinant Fusion Proteins - administration & dosage, Visual Acuity